In any case, PASK inhibits glucagon secretion and decreases the blood glucose level; therefore, it is theoretically possible to treat such metabolic diseases as insulin resistance, inadequate insulin secretion, and type II diabetes by effectively regulating glucagon and insulin secretion [14]. This evidence concerns the gene GCG and Insulin resistance.